Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Belada D, Kopeckova K, Bergua Burgues JM, Stevens D, André M, Persona EP, Pichler P, Staber PB, Trneny M, Duell J, Waldron-Lynch M, Wagner S, Mukhopadhyay A, Dirnberger-Hertweck M, Burke JM, Nowakowski GS.
Belada D, et al. Among authors: kopeckova k.
Blood. 2023 Oct 19;142(16):1348-1358. doi: 10.1182/blood.2023020637.
Blood. 2023.
PMID: 37369099
Free PMC article.
Clinical Trial.